Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Aclaris Therapeutics, Inc. (ACRS)  
$1.20 0.01 (0.84%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 74,043,000
Market Cap: 88.85(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.6449 - $10.95
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    : 4.6
Insider 6 Months    : 4.6
Insider 3/6 Months : 9.7
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Aclaris Therapeutics is a biopharmaceutical company that develops drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes Zunsemetinib, which is for the indication of rheumatoid arthritis (moderate to severe), psoriatic arthritis (moderate to severe), and hidradenitis suppurativa (moderate to severe); ATI-1777, which is for the indication of atopic dermatitis (moderate to severe); ATI-2138, which is for the indication of T cell-mediated autoimmune diseases; Gut-Biased Program, which is for the indication of inflammatory bowel disease; and ATI-2231, which is for the indication of metastatic breast cancer and pancreatic cancer.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 14,500 14,500 38,695 51,495
Total Buy Value $17,955 $17,955 $192,885 $292,695
Total People Bought 1 1 3 4
Total Buy Transactions 2 2 4 6
Total Shares Sold 0 0 18,000 418,803
Total Sell Value $0 $0 $136,018 $6,319,950
Total People Sold 0 0 1 5
Total Sell Transactions 0 0 3 29
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 402
  Page 1 of 17  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Walker Neal INTERIM PRESIDENT AND CEO   •       •      –    2024-04-01 4 D $1.26 $4,062 D/D (3,224) 1,285,688     -
   Walker Neal INTERIM PRESIDENT AND CEO   •       •      –    2024-04-01 4 OE $0.00 $0 D/D 9,467 1,288,912     -
   Powell Andrew Kenneth William Director   –       •      –    2024-03-04 4 B $1.25 $7,500 D/D 6,000 28,863 2.39 -5%     
   Balthaser Kevin Chief Financial Officer   •       –      –    2024-03-02 4 D $1.24 $529 D/D (427) 23,983     -
   Balthaser Kevin Chief Financial Officer   •       –      –    2024-03-02 4 OE $0.00 $0 D/D 1,500 24,410     -
   Monahan Joseph Chief Scientific Officer   •       –      –    2024-03-02 4 D $1.24 $4,378 D/D (3,531) 186,783     -
   Monahan Joseph Chief Scientific Officer   •       –      –    2024-03-02 4 OE $0.00 $0 D/D 12,500 190,314     -
   Balthaser Kevin Chief Financial Officer   •       –      –    2024-03-01 4 D $1.24 $1,228 D/D (990) 22,910     -
   Balthaser Kevin Chief Financial Officer   •       –      –    2024-03-01 4 OE $0.00 $0 D/D 3,475 23,587     -
   Walker Neal Interim President and CEO   •       •      –    2024-03-01 4 D $1.24 $3,997 D/D (3,223) 1,279,445     -
   Walker Neal Interim President and CEO   •       •      –    2024-03-01 4 OE $0.00 $0 D/D 9,466 1,282,668     -
   Powell Andrew Kenneth William Director   –       •      –    2024-03-01 4 B $1.23 $10,455 D/D 8,500 22,863 2.39 -4%     
   Monahan Joseph Chief Scientific Officer   •       –      –    2024-03-01 4 D $1.24 $22,012 D/D (17,752) 177,814     -
   Monahan Joseph Chief Scientific Officer   •       –      –    2024-03-01 4 OE $0.00 $0 D/D 60,925 180,997     -
   Leonard Braden Michael   –       –       •   2024-02-07 3 IO $0.00 $0 I/I 0 9,395,934 12%     
   Loerop James Chief Business Officer   •       –      –    2024-02-01 4 D $1.20 $7,705 D/D (6,421) 34,017     -
   Loerop James Chief Business Officer   •       –      –    2024-02-01 4 OE $0.00 $0 D/D 18,750 36,585     -
   Monahan Joseph Chief Scientific Officer   •       –      –    2024-02-01 4 D $1.20 $3,100 D/D (2,583) 134,641     -
   Monahan Joseph Chief Scientific Officer   •       –      –    2024-02-01 4 OE $0.00 $0 D/D 7,500 137,224     -
   Manion Douglas J. Pres and CEO   •       •      –    2024-01-01 4 D $1.05 $9,581 D/D (9,125) 41,813     -
   Manion Douglas J. Pres and CEO   •       •      –    2024-01-01 4 OE $0.00 $0 D/D 27,000 50,938     -
   Balthaser Kevin Chief Financial Officer   •       –      –    2024-01-01 4 D $1.05 $2,663 D/D (2,536) 20,425     -
   Balthaser Kevin Chief Financial Officer   •       –      –    2024-01-01 4 OE $0.00 $0 D/D 7,500 22,961     -
   Monahan Joseph Chief Scientific Officer   •       –      –    2023-10-23 4 AS $5.08 $30,460 D/D (6,000) 129,724 -75%     
   Balthaser Kevin Chief Financial Officer   •       –      –    2023-09-06 4 B $7.90 $74,971 D/D 9,490 15,461 2.74 -85%     
  402 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 17
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us